Kincell Bio News and Resources

Kincell Bio, a cell therapy development and manufacturing company, has closed a $22 million funding round to accelerate its growth as a CDMO for advanced therapies. The investment was led by NewSpring Capital through its NewSpring Healthcare strategy, alongside continued

Kincell Bio, a cell therapy development and manufacturing organisation, has announced the appointment of Mark R. Bamforth as Chief Executive Officer (CEO). Effective immediately, Bamforth brings decades of experience in the biopharmaceutical industry to the role, having founded and led

Kincell Bio, a cell therapy contract development and manufacturing organisation (CDMO), has entered into a new multi-year agreement with a clinical-stage cell therapy company. The partnership will focus on producing patient-specific batches of clinical-grade cell therapy products at Kincell’s facility

Kincell Bio has announced a new multi-year partnership with a leading biotechnology company for the production of early-phase clinical material of an allogeneic cell therapy product. The contract follows Kincell Bio’s acquisition of a GMP-ready facility in April 2024. This